Professor Zhong-Ming Qian received his M.D. from Peking University of the PRC in 1981 and his Ph.D. from University of Western Australia, Australia in 1993. From 1993 to 2012, he worked as a lecturer, assistant professor, associate professor and then as a full professor at the Hong Kong Polytechnic University. Since September of 2012, he has been serving as a Chair Professor at Fudan University School of Pharmacy in Shanghai of the PRC. In addition, he previously was a visiting professor at Yale University (2008-2009) and a Ph.D. joint-supervisor at Peking University (2001- 2006) and the Chinese Academy of Sciences (2001-2008). His research interests are in the areas of iron metabolism, the linking of brain iron misregulation with neurodegenerative disorders, and the associated neuropharmacology.
He has published more than 160 papers in SCI journals, including those in Lancet Neurology, Pharmacological Reviews, Neuron, Hepatology, Trends in Pharmacological Science, Trends in Molecular Medicine, Nature Communication, and Progress of Neurobiology. Based on his studies and the accumulated information, he proposed for the first time that brain iron misregulation is an initial cause of neuronal death at least in some neurodegenerative disorders and that the misregulation of iron metabolism might be the result of either genetic or non-genetic factors (Trend Mol Med, 2001). These viewpoints have been well confirmed by a numbers of new evidence from other laboratories.
Brain iron metabolism and neurodegenerative diseases; Neuropharmacology; Hepcidin; Development of traditional Chinese medicine-based products for treatment of iron-associated diseases
Education
Master Degree in Medicine (1981)
Department of Physiology & Pathophysiology, Peking University, Beijing, PRC
Ph.D. (1993)
Department of Physiology, University of Western Australia, Nedlands, WA, AUSTRALIA
Professional Experiences
11/1993 - 08/2012
Lecturer, Assistant Professor, Associate Professor, Professor
Department of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Kowloon, HONG KONG
09/2012 - Present
Chair Professor
Laboratory of Neuropharmacology, Fudan University School of Pharmacy Shanghai 201203, PRC
Teaching Activities
Physiology for Physical Scientists (M.Sc. Applied Sciences)
Toxicology (BSc Applied Biology and Biotechnology)
Pharmacology (BSc Applied Biology and Biotechnology)
Human Biology (BSc (Hon) Nursing)
Human Biology (PeD Nursing Education)
Foundation Physiology (BSc Physiotherapy)
Foundation Physiology (BSc Occupational Therapy)
Foundation Physiology (BSc Prosthetist & Orthotist [P&O])
Physiological Phenomena in Health & Illness (PeD Nursing)
Course Development: (MSc/PgD Course in Med Engineer & BSc in P&O)
In Hong Kong Polytechnic University
Grants & Projects
1993-2011 in Hong Kong polytechnic University
The Competitive Earmarked Grants of The Hong Kong Research Grants Council, etc / 48 grants/ 46，110，000.00 HKD
2012-present in Fudan University
1. National Key Basic Research Development Plan (973) / The role of iron in the development of Parkinson's Disease. (2011CB510004) / Group leader (5860T) 2011-2015
2. National Key Basic Research Development Plan (973 Plan) / Iron and the secondary neuronal injury after intracerebral hemorrhage (2014CB541604) / Sub-project Leader (2600T) 2014-2018
3. National Natural Science Foundation of China / Hepcidin and brain iron homeostasis (31271132) / Project Leader (850T) 2013-2016
4. National Natural Science Foundation of China (Key Project) / IL-6 /STAT3 pathway and hepcidin expression in the brain (31330035) / Project Leader (2850T) 2014-2018
5. National Natural Science Foundation of China / Hydrogen sulphide and hepcidin expression in the brain (31571195) / Project Leader (630T) 2016-2019
Awards & Honors
1. Postgraduate Scholarship of the University of Western Australia (1988-1992)
2. The President’s Award for Outstanding Performance/Achievement in Research and Scholarly Activities, The Hong Kong Polytechnic University (2001)
3. Prize for Scientific and Technological Progress of Ho Leung Ho Lee Foundation- 2009 (“Medical Sciences and Materia Medica” group)
Memberships
1. Vice Chairman, Chinese Society of Pharmacology of Pharmaceutical Industry (2004)
2. Member of the Standing Committee, Chinese Society of Applied Pharmacology (2004)
3. Vice Chairman, International Association of Biopharmacology and Biotechnology (2008)
4. Editor or Editorial Board Member of 27 Journals, including Frontiers in Neuroscience and Annals of Pharmacology & Pharmaceutics, etc
Invited Presentations
More than 200 times
Selected Publications（latest 5 yrs，<20 papers）
1. Zhou YF, Wu XM, Zhou G, Mu MD, Zhang FL, Li FM, Qian C, Du F, Yung WH, Qian ZM*, Ke Y*. Cystathionine β-synthase is required for body iron homeostasis. Hepatology 2018 Jan;67(1):21-35. doi: 10.1002/hep.29499.
2. Li Q, Ko H, Qian ZM, Yan LYC, Chan DCW, Arbuthnott G, Ke Y, Yung WH. Refinement of learned skilled movement representation in motor cortex deep output layer. Nat Commun 2017 Jun 9;8:15834. doi: 10.1038/ncomms15834.
3. Zhang FL, Hou HM, Yin ZN, Chang L, Li FM, Chen YJ, Ke Y*, Qian ZM*. Impairment of Hepcidin Upregulation by Lipopolysaccharide in the Interleukin-6 Knockout Mouse Brain. Front Mol Neurosci 2017 Nov 7;10:367. doi: 10.3389/fnmol.2017.00367.
4. Zhou YF, Zhang C, Yang G, Qian ZM*, Zhang MW, Ma J, Zhang FL, Ke Y*. Hepcidin Protects Neuron from Hemin-Mediated Injury by Reducing Iron. Front Physiol 2017 May 23; 8:332. doi: 10.3389/fphys.2017.00332.
5. Wu XM, Qian C, Zhou YF, Yan YC, Luo QQ, Yung WH, Zhang FL, Jiang LR, Qian ZM*, Ke Y*. Bi-directionally protective communication between neurons and astrocytes under ischemia. Redox Biol 2017 May 20; 13:20-31. doi: 10.1016/j.redox.2017.05.010.
6. Lou QQ, Zhou YF, Chen YJ, Liu L, Ma J, Zhang MW, Zhang FL, Ke Y*, Qian ZM*. Ghrelin promotes ferroportin 1 expression via a GHSR/MAPK signaling pathway. J Cell Physiol 2018 Jan; 233(1):30-37. doi: 10.1002/jcp.25931.
7. Yu SS, Jiang LR, Ling Y, Qian ZM*, Zhou YF, Li J, Ke Y*. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol 2017 Feb 13; 8:60. doi: 10.3389/fphar.2017.00060. eCollection 2017.
8. Wang PP, Wu L, Ju Y, Qian ZM*, Wang R*. Age-dependent Allergic Asthma Development and Cystathionine gamma-Lyase Deficiency. Antioxid Redox Signal 2017 Nov 1; 27(13): 931-944. doi: 10.1089/ars.2016.6875
9. Lu LN, Qian ZM*, Wu KC, Yung WH, Ke Y*. Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats. Mol Neurobiol 2017 Sep; 54(7):5213-5224. doi: 10.1007/s12035-016-0067-0.
10. Zhu ZJ, Wu KC, Yung WH, Qian ZM*, Ke Y*. Differential interaction between iron and mutant alpha-synuclein causes distinctive Parkinsonian phenotypes in Drosophila. Biochim Biophys Acta 2016 Apr; 1862(4): 518-525. doi: 10.1016/j.bbadis.2016.01.002.
11. Gong J, Du F, Qian ZM*, Luo QQ, Sheng Y, Yung WH, Xu YX, Ke Y*. Pre-treatment of rats with ad-hepcidin prevents iron-induced oxidative stress in the brain. Free Radic Biol Med 2016 Jan; 90:126-32. doi: 10.1016/j.freeradbiomed.2015.11.016.
12. Wu XM, Liu Y, Qian ZM*, Luo QQ, Ke Y*. CX3CL1/CX3CR1 axis plays a key role in ischemia-induced oligodendrocyte injury via p38MAPK signaling pathway. Mol Neurobiol 2016 Aug; 53(6):4010-4018. doi: 10.1007/s12035-015-9339-3
13. Liu Y, Wu XM, Luo QQ, Huang S, Yang QW, Wang FX, Ke Y*, Qian ZM*. CX3CL1/CX3CR1-mediated microglia activation plays a detrimental role in ischemic mice brain via p38MAPK/PKC pathway. J Cereb Blood Flow Metab 2015 Oct; 35(10):1623-31. doi: 10.1038/jcbfm.2015.97
14. Du F, Qian ZM*, Luo Q, Yung WH, Ke Y*. Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in iron-overloaded rats. Mol Neurobiol 2015 Aug; 52(1):101-114. doi: 10.1007/s12035-014-8847-x.
15. Qian ZM*, He X, Lu LN, Wu KC, Yan YC, Yang G, Luo QQ, Yung WH, Ke Y*. Lipopolysaccharides upregulate hepcidin expression in the neurons via microglia and the IL-6/STAT3 signaling pathway. Mol Neurobiol 2014 Mar 23. 50(3):811-820. doi: 10.1007/s12035-014-8671-3
16. Qian ZM, Ke Y. Huperzine A: is it an effective disease-modifying drug for Alzheimer’s disease? Front Aging Neurosci 2014 Aug 19;6:216. doi: 10.3389/fnagi.2014.00216.
17. Li L, Xiong ZY, Qian ZM*, Zhao TZ, Feng H, Hu S, Hu R, Ke Y, Lin J. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice. Neurobiol Dis 2014 Jun; 66:74-82. doi: 10.1016/j.nbd.2014.02.008
18. Huang XT, Qian ZM*, He X, Gong Q, Zhu ZJ, Lu LN, Wu KC, Zhang HY, Xin H, Yung WH, Ke Y. Reducing iron in the brain: a novel pharmacological mechanism of Huperzine A in the treatment of Alzheimer’s Disease. Neurobiol Aging 2014 May; 35(5):1045-1054. doi: 10.1016/j.neurobiolaging.2013.11.004
19. Li Q, Qian ZM, Arbuthnott GW, Ke Y, Yung WH. Cortical Effects of Deep Brain Stimulation Implications for Pathogenesis and Treatment of Parkinson Disease. JAMA Neurol 2014 Jan 1; 71(1):100-103. doi: 10.1001/jamaneurol.2013.4221.
20. Li Q, Ke Y, Chan DC, Qian ZM, Yung KK, Ko H, Arbuthnott GW, Yung WH. Therapeutic deep brain stimulation in parkinsonian rats directly influences motor cortex. Neuron 2012 Dec 6; 76(5):1030-1041. doi: 10.1016/j.neuron.2012.09.032.
Patents
Authorized 13 patents
